Effects of growth hormone therapy on serum resistin, leptin, and FGF-23 levels in children with growth hormone deficiency
ZHENG Zeyan, ZHOU Zhibo, SUN Yunxin, GUO Xiaoyuan, ZHU Huijuan, PAN Hui
2026, 46(5):
687-693.
doi:10.16352/j.issn.1001-6325.2026.05.0687
Asbtract
(
29 )
PDF (989KB)
(
9
)
References |
Related Articles |
Metrics
Objective To compare serum level of resistin, leptin, and fibroblast growth factor 23(FGF-23)in children with growth hormone deficiency(GHD), children with idiopathic short stature(ISS), and healthy(children) control(HC) in order to evaluate the dynamic effects and clinical significance of one-year growth hormone(GH) therapy on these biomarkers. Methods This prospective cohort study enrolled 25 children with GHD, 25 children with ISS and 30 healthy children. Children with GHD received one-year growth hormone therapy. Fasting venous blood samples were collected before growth hormone therapy and at 6 and 12 months during treatment. Serum resistin, leptin, and FGF-23 levels were measured using ELISA. Clinical parameters including height, weight, growth velocity(GV),insulin-like growth factor 1(IGF-1), lipid profiles, fasting blood glucose(FBG), and homeostatic model assessment of insulin resistance(HOMA-IR) were collected at the same time. A linear mixed-effects model was used to adjust for confounders and evaluate indicator changes. Results The baseline level of serum resistin and FGF-23 in the GHD group was significantly higher than those in the healthy controls group(P<0.05), leptin level was significantly higher than those in the ISS group(P<0.05). After one-year GH therapy all three biomarkers significantly decreased in GHD children(P<0.01) and was still significant after adjustment for age, gender, body mass index standard deviation score(BMI SDS), and IGF-1 standard deviation score(IGF-1 SDS). Concurrently, height standard deviation score(Ht SDS) improved from(-1.8±0.7) to(-1.5±2.2), annual growth velocity increased from(4.6±1.1)cm/year to(9.3±1.7)cm/year, and IGF-1 SDS significantly increased(P<0.001). During treatment, FBG and triglyceride level mildly increased(P<0.05,P<0.01), but still kept within normal reference ranges; other metabolic parameters showed no significant changes. Conclusions GH therapy significantly improves linear growth and reduces resistin, leptin, and FGF-23 levels in children with GHD, demonstrating good short-term metabolic safety.